The PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody from Spring Bioscience, Pleasanton, Calif, offers a sensitive and specific method to stain and analyze both tumor and immune cells. The PD-L1 clone was developed for Roche/Genentech’s anti-PD-L1 (MPDL3280A) immunotherapy development program and included in research of various tumor types. As pharmaceutical companies continue to research and develop cancer drugs that target the immune system, measuring the amount of PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells may help assess the efficacy and durability of investigational drugs that inhibit the binding of the PD-L1 protein. Internal comparison studies performed at Spring demonstrated that the PD-L1 (SP142) antibody outperformed other commercially available PD-L1 antibodies. For more information, visit Spring Bioscience.
Antibody for Immunotherapy Research
